Elizabeth Bhatt
Directeur/Bestuurslid bij EFFECTOR THERAPEUTICS, INC.
Vermogen: 653 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Stephen Worland | M | 66 | 12 jaar | |
Brian Gallagher | M | 54 | 4 jaar | |
Jeffrey Finer | M | - |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | - |
Christopher Ehrlich | M | 54 | 3 jaar | |
Andrew Dickinson | M | 54 | 8 jaar | |
Barbara Klencke | M | 66 | 3 jaar | |
Michael Byrnes | M | 47 | 4 jaar | |
Kelly Kramer | F | 56 | 8 jaar | |
Kristen Harrington-Smith | F | 51 | 2 jaar | |
Caroline Loewy | F | 58 | 1 jaar | |
Jeffrey Tong | M | 48 |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | - |
Mayank J. Gandhi | M | 47 | 2 jaar | |
Linda Higgins | M | 62 | 14 jaar | |
Jennifer Doudna | M | 60 | - | |
Abraham Bassan | M | 39 |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | 3 jaar |
Mark Densel | M | - | 6 jaar | |
Michael Hodges | M | - | - | |
Douglas Warner | M | 52 | 2 jaar | |
Robert Cook | M | 65 | 12 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 99 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Elizabeth Bhatt
- Persoonlijk netwerk